Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
[HTML][HTML] Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies
The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …
[HTML][HTML] Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …
important component of the comprehensive response to the severe acute respiratory …
[HTML][HTML] Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
Background COVID-19 is associated with increased risks of neurological and psychiatric
sequelae in the weeks and months thereafter. How long these risks remain, whether they …
sequelae in the weeks and months thereafter. How long these risks remain, whether they …
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
[HTML][HTML] Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform …
G Reis, EA dos Santos Moreira-Silva… - The Lancet Global …, 2022 - thelancet.com
Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …
Neurological manifestations of long-COVID syndrome: a narrative review
MI Stefanou, L Palaiodimou, E Bakola… - … advances in chronic …, 2022 - journals.sagepub.com
Accumulating evidence points toward a very high prevalence of prolonged neurological
symptoms among coronavirus disease 2019 (COVID-19) survivors. To date, there are no …
symptoms among coronavirus disease 2019 (COVID-19) survivors. To date, there are no …
[HTML][HTML] Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
S Ramakrishnan, DV Nicolau, B Langford… - The Lancet …, 2021 - thelancet.com
Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …
that patients with chronic respiratory disease were significantly under-represented in these …
[HTML][HTML] Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide
over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors …
over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors …
[HTML][HTML] Host-directed immunotherapy of viral and bacterial infections: past, present and future
The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …